Remifentanil
- Generic Name
- Remifentanil
- Brand Names
- Ultiva
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5
- CAS Number
- 132875-61-7
- Unique Ingredient Identifier
- P10582JYYK
- Background
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
- Indication
For use during the induction and maintenance of general anesthesia.
- Associated Conditions
- -
- Associated Therapies
- Immediate postoperative analgesia therapy, Induction and Maintenance of General Anesthesia, Monitored anesthesia care sedation
Optimal Concentration of Remifentanil for NIM Tube Intubation With Low-dose NMBA
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Kyungpook National University Chilgok Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT06162390
- Locations
- 🇰🇷
Sung Hye Byun, Daegu, Korea, Republic of
Effects of Dexmetomidine and Remifentanil Used for Controlled Hypotension in Septorhinoplasty Surgery on Cardiac Electrophysiology: Prospective Randomized Study
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 72
- Registration Number
- NCT06138574
Effects of Sufentanil on the Intraoperative Hemodynamics
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 92
- Registration Number
- NCT06091904
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT06003218
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
The Effect of Remimazolam on Opioid Induced Hyperalgesia
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Wonkwang University Hospital
- Target Recruit Count
- 108
- Registration Number
- NCT05866315
- Locations
- 🇰🇷
Wonkwag UH, Iksan, Jeollabukdo, Korea, Republic of
🇰🇷Wonkwang University hospital, Iksan, Korea, Republic of
Step 2 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients
- Conditions
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 164
- Registration Number
- NCT05782894
- Locations
- 🇨🇳
Wuhan Union Hospital, Wuhan, Hubei, China
COMPARISON OF DEXMEDETOMIDINE AND REMIFENTANIL FOR POSTOPERATIVE PAIN IN TRANSPHENOIDAL Pituitary SURGERY
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Kocaeli University
- Target Recruit Count
- 84
- Registration Number
- NCT05772832
- Locations
- 🇹🇷
University of Kocaeli, Kocaeli, Izmit, Turkey
Electroencephalogram Based Real-Time Sedation Level Prediction
- Conditions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 1000
- Registration Number
- NCT05757622
Median Effective Dose of Remifentanil for the Prevention of Myoclonus Induced by Etomidate Injection
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Yangzhou University
- Target Recruit Count
- 70
- Registration Number
- NCT05754762
Opioid Sparing Anesthesia in Cervical Spine Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Evangelismos Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05717361
- Locations
- 🇬🇷
Evangelismos General Hospital, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.